title: Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
authors.forename: Michaël
authors.initials: M
authors.lastname: Darmon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Guichard
authors.forename: François
authors.initials: F
authors.lastname: Vincent
mesh_terms: D000328:Adult; D002648:Child; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D006074:Gout Suppressants / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D054559:Hyperphosphatemia / Q000517:prevention & control; D033461:Hyperuricemia / Q000188:drug therapy*; D015275:Tumor Lysis Syndrome / Q000517:prevention & control*; D014503:Urate Oxidase / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*
chemical_list: D006074:Gout Suppressants; C469709:rasburicase; D014503:Urate Oxidase